
Strides Pharma Science Limited
Indian global pharmaceutical company headquartered in Bengaluru, founded in 1990 by Arun Kumar. Listed on the NSE (STAR) and BSE (532531), Strides develops and manufactures generic and specialty pharmaceuticals for regulated and emerging markets, and holds the US new drug application for the asthma drug Accolate.
Company Type
public
Founded
1990
Headquarters
Bengaluru, Karnataka, India
Stock
NSE, BSE (532531): STAR
Revenue
approximately INR 48,587 million (FY2026)
Employees
approximately 4,000
Primary Market
Global
Strides Pharma Science Limited Timeline
Shop Strides Pharma Science Limited Brands
Disclosure: We may earn commission from purchasesAbout Strides Pharma Science Limited
Who owns Strides Pharma Science?
Strides is publicly traded on India's NSE (STAR) and BSE (532531). Founder Arun Kumar leads the company as chairman, and ownership is divided among the promoter group, institutional investors, and public shareholders.
Is Strides Pharma Science publicly traded?
Yes. Strides trades on the National Stock Exchange of India under ticker STAR and on the Bombay Stock Exchange under code 532531. It is not listed on US or European exchanges.
How many brands does Strides Pharma Science own?
Strides owns a broad portfolio of generic and branded pharmaceutical products rather than consumer-style brands. Its notable US asset is the new drug application for Accolate, the asthma medicine whose American rights it holds after transfer from AstraZeneca.
Where is Strides Pharma Science headquartered?
The company is headquartered in Bengaluru, Karnataka, India, and operates manufacturing sites in India along with international facilities supporting its US, regulated-market, and African businesses.
When was Strides Pharma Science founded?
Arun Kumar founded the company in 1990 in Bengaluru. It grew from a domestic Indian pharma firm into a global generics and specialty manufacturer listed on Indian exchanges.
What is Strides Pharma Science's revenue?
Strides reported revenue of approximately INR 48,587 million for fiscal year 2026, making it a mid-sized player among India's listed pharmaceutical companies.
History of Strides Pharma Science Limited
Arun Kumar founded Strides in 1990 in Bengaluru, then called Bangalore, building it from a domestic Indian pharmaceutical firm into a global generics manufacturer. Through the 1990s and 2000s the company expanded into formulations, active pharmaceutical ingredients, and contract manufacturing for regulated markets.
The company underwent several restructurings as it grew, including the renaming and reorganization that produced the current Strides Pharma Science Limited entity focused on finished dosage pharmaceuticals. Earlier iterations of the group included businesses in biotech and specialty ingredients that were separated or divested as the company sharpened its generics focus.
Strides built a meaningful US generics business through its American subsidiary, winning ANDA approvals across oral solids and other dosage forms, and expanded into regulated markets including Australia and Europe alongside a large emerging-markets presence in Africa. Its manufacturing network grew to include multiple Indian plants and international sites.
A notable portfolio addition came through acquisition of US new drug application rights, including the NDA for Accolate (zafirlukast), an asthma leukotriene inhibitor originally developed by AstraZeneca. That transfer moved the US brand-ownership relationship for Accolate from the originator to Strides, making the Indian company the legal US owner of the branded drug.
By fiscal year 2026 Strides reported revenue of approximately INR 48,587 million, and in October 2026 it reported quarterly results for the second quarter of fiscal 2027, continuing its trajectory as a mid-cap Indian pharma company competing in global generics.
Strides Pharma Science Limited Sustainability & Ethics
As a mid-cap Indian pharmaceutical company, Strides publishes the regulatory ESG disclosures required of Indian listed firms rather than holding independent certifications. Its reporting covers manufacturing environmental compliance, employee safety, and access-to-medicines positioning in the African and Asian markets it serves.
The company has emphasized its role supplying affordable medicines to lower-income markets as a core social contribution, consistent with its emerging markets business, though it holds no third-party certification such as B Corp.
Controversy, Regulation & Public Scrutiny
Strides, like all pharmaceutical manufacturers supplying regulated markets, is subject to periodic regulatory inspections and compliance actions by the US FDA and other agencies at its manufacturing sites. No systemic quality scandal has been associated with the company through 2026.
The company has navigated the ordinary legal and commercial disputes of the generics industry, including patent litigation inherent to filing ANDAs and the business of acquiring and transferring drug applications such as the Accolate NDA.
Brands Owned by Strides Pharma Science Limited
Strides Pharma Science Limited owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Strides Pharma Science Limited
public · Founded 1990 · Bengaluru, Karnataka, India
1
brands
Stock Information
Strides Pharma Science Limited Ownership: Pros & Cons
Advantages
- +Public listing provides access to capital markets for growth funding
- +Founder-led management offers strategic continuity since 1990
- +Ownership of US NDAs including Accolate adds branded revenue alongside generics
- +Differentiated-dosage-form focus reduces commodity generic pressure
- +Diversified across regulated and emerging markets
Considerations
- -Mid-cap scale limits R&D depth versus larger Indian peers like Sun Pharma
- -US generics market faces persistent pricing erosion
- -Regulatory compliance risk at manufacturing sites can disrupt supply
- -Founder-chairman concentration places strategic control with one leader
- -Exposure to the volatile African institutional business adds earnings variability
Frequently Asked Questions About Strides Pharma Science Limited
Who owns Strides Pharma Science?
Strides is publicly traded on India's NSE (STAR) and BSE (532531). Founder Arun Kumar leads the company as chairman, and ownership is divided among the promoter group, institutional investors, and public shareholders.
Is Strides Pharma Science publicly traded?
Yes. Strides trades on the National Stock Exchange of India under ticker STAR and on the Bombay Stock Exchange under code 532531. It is not listed on US or European exchanges.
How many brands does Strides Pharma Science own?
Strides owns a broad portfolio of generic and branded pharmaceutical products rather than consumer-style brands. Its notable US asset is the new drug application for Accolate, the asthma medicine whose American rights it holds after transfer from AstraZeneca.
Where is Strides Pharma Science headquartered?
The company is headquartered in Bengaluru, Karnataka, India, and operates manufacturing sites in India along with international facilities supporting its US, regulated-market, and African businesses.
When was Strides Pharma Science founded?
Arun Kumar founded the company in 1990 in Bengaluru. It grew from a domestic Indian pharma firm into a global generics and specialty manufacturer listed on Indian exchanges.
What is Strides Pharma Science's revenue?
Strides reported revenue of approximately INR 48,587 million for fiscal year 2026, making it a mid-sized player among India's listed pharmaceutical companies.








